Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -53.40% and Operating profit at 0% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0 times
Flat results in Dec 25
Risky - Negative EBITDA
Stock DNA
Pharmaceuticals & Drugs
INR 42 Cr ()
NA (Loss Making)
37
0.00%
0.00
0.00%
-0.20
Total Returns (Price + Dividend) 
Latest dividend: 0.4 per share ex-dividend date: Sep-19-2018
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
22-Jul-2026 | Source : BSEnews paper publication for march 2026 results
Re- Lodgement Of Transfer Requests
22-Jul-2026 | Source : BSEre-lodgement of transfer requests
Results As On 31.3.2026
17-Jul-2026 | Source : BSEresults for FY 2025-2026
Corporate Actions 
No Upcoming Board Meetings
Vivimed Labs Ltd has declared 20% dividend, ex-date: 19 Sep 18
Vivimed Labs Ltd has announced 2:10 stock split, ex-date: 06 Apr 16
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Non Institution
15.1806
Held by 0 Schemes
Held by 5 FIIs (1.64%)
Varalwar Sandeep (2.81%)
Kitara Piin 1102 (9.37%)
68.75%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is -35.08% vs -48.49% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is -757.57% vs -274.89% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -39.80% vs -37.86% in Mar 2025
YoY Growth in year ended Mar 2026 is -452.16% vs 90.27% in Mar 2025